WF
CMPX icon

Welch & Forbes’s Compass Therapeutics CMPX Stock Holding History

Welch & Forbes’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Hold
19,000
– – ﹤0.01% 365
2025
Q4 		$102K Buy
19,000
+4,000
+27% +$18.5K ﹤0.01% 373
2025
Q3 		$52.5K Buy
+15,000
New +$47.4K ﹤0.01% 383

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Welch & Forbes's CMPX Position: Q1 2026 in Review

Welch & Forbes held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 19,000 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Welch & Forbes first reported a position in CMPX in Q3 2025 and has held it in 3 quarters since. The position peaked at $102K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Welch & Forbes held 19,000 shares of Compass Therapeutics worth $101K as of Q1 2026.
  • Welch & Forbes left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Welch & Forbes's portfolio in Q1 2026, its #365 holding.
  • Welch & Forbes first reported a position in Compass Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Welch & Forbes's Compass Therapeutics position peaked at $102K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Welch & Forbes's 13F filing for Q1 2026, filed 1 May 2026.